Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) insider Barbara White bought 2,836 shares of the business’s stock in a transaction that occurred on Friday, November 10th. The shares were acquired at an average price of $7.00 per share, for a total transaction of $19,852.00. Following the transaction, the insider now owns 174,050 shares in the company, valued at $1,218,350. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) opened at $6.82 on Tuesday. Corbus Pharmaceuticals Holdings, Inc. has a 52-week low of $5.30 and a 52-week high of $10.50.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.02. The business had revenue of $0.80 million for the quarter. Corbus Pharmaceuticals Holdings had a negative return on equity of 96.02% and a negative net margin of 1,040.41%. equities analysts expect that Corbus Pharmaceuticals Holdings, Inc. will post -0.63 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Corbus Pharmaceuticals Holdings, Inc. (CRBP) Insider Barbara White Buys 2,836 Shares of Stock” was posted by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.watchlistnews.com/corbus-pharmaceuticals-holdings-inc-crbp-insider-barbara-white-buys-2836-shares-of-stock/1702324.html.

CRBP has been the topic of several research analyst reports. Noble Financial upped their target price on Corbus Pharmaceuticals Holdings from $16.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, November 8th. BidaskClub upgraded Corbus Pharmaceuticals Holdings from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. ValuEngine lowered Corbus Pharmaceuticals Holdings from a “hold” rating to a “sell” rating in a research report on Wednesday, September 13th. Finally, Cantor Fitzgerald set a $24.00 target price on Corbus Pharmaceuticals Holdings and gave the company a “buy” rating in a research report on Monday, July 17th. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $20.75.

A number of large investors have recently made changes to their positions in CRBP. State Board of Administration of Florida Retirement System bought a new position in Corbus Pharmaceuticals Holdings in the third quarter worth approximately $108,000. Voya Investment Management LLC bought a new position in Corbus Pharmaceuticals Holdings in the second quarter worth approximately $125,000. Capital Fund Management S.A. bought a new position in Corbus Pharmaceuticals Holdings in the second quarter worth approximately $130,000. Credit Suisse AG bought a new position in Corbus Pharmaceuticals Holdings in the first quarter worth approximately $157,000. Finally, Nationwide Fund Advisors bought a new position in Corbus Pharmaceuticals Holdings in the second quarter worth approximately $158,000. Institutional investors and hedge funds own 29.20% of the company’s stock.

About Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Insider Buying and Selling by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)

Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.